Sysmex UK
Menu

OSNA in breast cancer

  • Precise lymph node analysis providing accurate staging
  • Reliable diagnostic information for therapy decision
  • High flexibility in multi-cancer application (CE-marked for breast, colon and gastric cancer)

Documents

All
  • All
  • Literature
Documents

More differentiated information to fine-tune your treatment decision

Axillary management and the relevance of sentinel lymph node biopsy (SLNB) have undergone major changes in the last years. Clinical trials, which have investigated less invasive treatment approaches as a replacement of axillary surgery, indicate that axillary dissection can be omitted in patients with limited metastatic involvement. Consequently, treatment decisions and nodal staging more often have to be based solely on the diagnostic information derived from the sentinel lymph node (SLN).

More than 100 publications provide evidence on the clinical utility of using OSNA and the CK19 copy number for SLN assessment. They show that CK19 provides predictive and prognostic information beyond conventional pathology assessment. This helps clinicians better select who can be safely spared an ALND, allows more personalised treatment decisions and improves patients’ quality of life.

Oncology

Do you get all this from your current sentinel lymph node analysis?

Do you get all this from your current sentinel lymph node analysis?

CK19 mRNA expression level:

Choose OSNA and fine-tune your treatment decision

Choose OSNA and fine-tune your treatment decision

Publications

Publications

Please see our publication list

Contact

SYSMEX UK LTD Sysmex House

0333 320 3460
info@sysmex.co.uk
Garamonde Drive, Wymbush
Milton Keynes
United Kingdom

Create Pdf
Enjoy our Media Centre
All
  • All
  • Documents
  • Podcast
  • Images
  • Videos
Sysmex Urinalysis
See the features